Objectives: The present investigation was designed to determine if atr
ial natriuretic peptide (ANP) gene expression increases in extracardia
c as well as within the heart in congestive heart failure. Methods: Co
ngestive heart failure (CHF) was induced by producing cardiac hypertro
phy secondary to an aortocaval fistula in Sprague-Dawley rats. To char
acterize this model, control and CHF rats had cardiac catheterizations
and transthoracic echocardiography. ANP messenger RNA was measured by
RNAase protection analysis in atria, ventricles, liver, colon, and st
omach of CHF and sham rats and quantitated by 2-D scanning, The produc
t of ANP gene expression was determined in each of these tissues with
high performance-gel permeation chromatography. To help determine if i
ncreased degradation of atrial natriuretic peptides occur in congestiv
e heart failure, the circulating concentrations and the excretion of t
he atrial natriuretic peptides into urine were measured by specific ra
dioimmunoassays, Results: ANP steady-state mRNA increased 4.2 +/- 0.05
and 4.3 +/- 0.06-fold, respectively, in the antrum of the stomach and
within the heart ventricle of CHF rats compared with age-matched sham
rats. ANP gene expression was present but not increased in atria, liv
er, and gastrointestinal tract of the CHF rats. High-performance gel p
ermeation chromatography revealed that the product of this ANP gene ex
pression within the stomach and heart ventricle in CHF animals was the
ANP prohormone. There was not any decrease in the metabolism of these
peptides by the kidney in CHF. Conclusions: ANP steady-state mRNA inc
reases in extracardiac (i.e., stomach antrum) tissue as well as in the
ventricle of the heart in CHF, The product of the ANP gene expression
, i.e., the ANP prohormone is the same in the extracardiac tissues as
within the heart. Whether the increased extracardiac ANP steady-state
mRNA and its resultant increased atrial natriuretic peptides helps pre
vent bowel wall edema in CHF needs to be elucidated.